HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Animal alternative tests

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program is seeking comments and nominations for validation studies of in vitro test methods for identifying endocrine disruptors, agency announces in April 21 Federal Register 1notice. NTP has thus far received two proposals, which were presented by the Interagency Coordinating Committee for the Validation of Alternative Methods at a March meeting of the Scientific Advisory Committee on Alternative Toxicological Methods (2"The Rose Sheet" March 22, 2004, p. 4). ICCVAM will receive comments and nominations and then "develop recommended priorities" for proposed methods, the notice states. In a separate Federal Register 3notice, the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods and ICCVAM report they are seeking nominations for scientific experts to evaluate in vitro test methods for identifying chemicals that potentially cause ocular irritancy...

You may also be interested in...



ICCVAM To Study Alternative Animal Test Feasibility For Ocular Irritation

The Interagency Coordinating Committee on the Validation of Alternative Methods will review four non-animal in vitro tests this year to assess whether they are predictive in identifying severe ocular irritants and corrosives, according to the group

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel